Gilead Sciences Inc (NAS:GILD)
$ 64.6 -0.34 (-0.52%) Market Cap: 80.48 Bil Enterprise Value: 98.68 Bil PE Ratio: 179.39 PB Ratio: 4.61 GF Score: 74/100

Gilead Sciences Inc at Goldman Sachs Global Healthcare Conference (Virtual) Transcript

Jun 09, 2021 / 06:10PM GMT
Release Date Price: $68.65 (+1.69%)
Terence C. Flynn
Goldman Sachs Group, Inc., Research Division - MD

Great. Good afternoon, everybody. I'm Terence Flynn, the U.S. biopharma analyst at Goldman Sachs. And thank you for joining us at our virtual conference. I'm very pleased to be hosting Gilead Sciences.

Today from the company, we have Andy Dickinson, who is the company's Chief Financial Officer. Andy, thanks so much for taking the time today to join us out of your busy day. Really appreciate it.

Andrew D. Dickinson
Gilead Sciences, Inc. - Executive VP & CFO

No, I'm happy to do it. Thanks for having us.

Questions & Answers

Terence C. Flynn
Goldman Sachs Group, Inc., Research Division - MD

So I think maybe just at a high level, I think one of the key questions that people are focused on here for Gilead is just the longer-term outlook on the growth side. And so as you think about the outlook there, what gives you the confidence that the company is positioned here to grow on a forward and a sustainable basis, Andy?

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot